Xofluza is the first and only single-dose oral medicine for the treatment of influenza to be approved in the US for children as young as five years of age
First and only PARP inhibitor to improve invasive disease-free survival, the primary endpoint, and overall survival, a key secondary endpoint, in these patients
First and only PARP inhibitor to improve invasive disease-free survival in patients
Avillion announces expansion of partnership with AstraZeneca on PT027 and will fund and execute a new Phase 3b study
Potential new treatment for progressive pulmonary fibrosis (PPF) builds on Boehringer Ingelheim’s leadership in lung fibrosis and will be further investigated in a phase III clinical trial program
Formula attenuates 99% of 365 coronaviruses in computer models
Pre-exposure prevention trial reduced risk of symptomatic Covid-19, with no severe disease or Covid-19-related deaths in the Evusheld group
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales)
Clinical improvements were consistent across patient subgroups including age, gender, ethnicity, and IL-36 gene mutation status
First PARP inhibitor to demonstrate overall survival benefit in early breast cancer
Subscribe To Our Newsletter & Stay Updated
